PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

Penumbra Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$322.41+1.55 (+0.48%)

Close on Oct 19, 2026

Market cap: $12.76B
P/E (TTM): 79.2
Dividend yield: –

Dividends

Penumbra has not reported a dividend

No dividend per share appears in Penumbra's annual filings since fiscal 2012.

Where these numbers come from

Parsed from the XBRL in Penumbra's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PEN.

Revenue growth17.6% · median 10.2%

Gross margin67.8% · median 52.5%

Operating margin12.4% · median 4.0%

Net margin10.7% · median 1.4%

Company	Revenue	Growth
TFX	$2.25B	+30.7%
ICUI	$2.16B	-9.0%
IART	$1.65B	+1.6%
MMSI	$1.58B	+10.2%
PEN	$1.50B	+17.6%
LMAT	$262.43M	+11.8%

Company

Next earnings (est.): Nov 4, 2026, after close
Exchange: NYSE
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 4,700
Held by institutions: 86.7%
Auditor: Deloitte & Touche LLP
SEC CIK: 1321732

Advertisement
300 × 250